• Pharmacologic approaches of inhibiting GSNOR activity

  2022-03-18

  

  Pharmacologic approaches of inhibiting GSNOR activity have reached the point of clinical development with the recent announcement of the first cystic fibrosis patients treated with the first-in-class GSNOR inhibitor, N6022 (N30 Pharmaceuticals). Clinical development is ongoing for other indications

• GPR levels were not changed by any treatment GPR has

  2022-03-18

  

  GPR40 levels were not changed by any treatment. GPR40 has the same agonists as GPR120 but only a 10% homology [35] despite using the same intracellular signaling cascades [7]. Previous data on the ability of exercise to modulate G protein coupled receptors in general are scarce. The long-chain fatty

• In addition to the role of TGR the FXR FGF

  2022-03-18

  

  In addition to the role of TGR5, the FXR-FGF15/19 axis has been implicated in other aspects of glucose metabolism and metabolic disorders. In humans, both obesity and type 2 diabetes mellitus (T2DM) are associated with lower plasma FGF19 levels [67,68]. A derivative of the naturally occurring FXR ag

• In previous work we showed that benzophenanthridines

  2022-03-18

  

  In previous work we showed that benzophenanthridines do not affect the surface expression of GlyT1 (Jursky and Baliova, 2011). The results from the surface biotinylation studies reported in Fig. 3 show that the surface expression of the Y370F mutant is not significanly affected by the alkaloids in t

• This resembles a vicious cycle since BBB

  2022-03-18

  

  This resembles a vicious cycle since BBB disruption and inflammation are thought to be caused by epilepsy, but other contributing factors are also known to be their cause, such as peripheral infection, autoimmunity, Biotin-azide trauma and stroke that also underlie epilepsy [18]. Additional triggers

• Studies dealing with the effects of ischemia on EAATs have

  2022-03-18

  

  Studies dealing with the effects of ischemia on EAATs have been previously reported, but some discrepancies in literature appear between them probably as a consequence of the different models, species, time of reperfusion after ischemia and age of the animals. Thus, in human, GSK1324726A stroke-depe

• It was previously proposed that

  2022-03-17

  

  It was previously proposed that glucagon acts in the liver, in which a signal is produced and relayed to the 8-Azido-ATP via vagal nerves [8], [36], [37]. The concept that the liver is the primary target site was supported by the studies reporting that the glucagon receptor is localized in the live

• It has also been demonstrated that PS is ubiquitinated

  2022-03-17

  

  It has also been demonstrated that PS1 is ubiquitinated by Caenorhabditis elegans SEL-10 [52], Fbw7 the mammalian homologue of SEL-10 [38], and more recently by tumour necrosis factor Nitrendipine associated factor 6 (TRAF6), which facilitates Lysine-63 (K63)-linked polyubiquitination of PS1 [50],

• Among sensitizers tested in the

  2022-03-17

  

  Among 22 sensitizers tested in the previous study, six test chemicals were pre- or pro-haptens (Nepal et al., 2018a). Among 6 chemicals, hydroquinone and 2-aminophenol, strong sensitizers, were falsely classified as non-sensitizers due to the lack of metabolic activation (Nepal et al., 2018a). Liter

• DNAzymes a series of nucleotide sequences with specific cata

  2022-03-17

  

  DNAzymes, a series of nucleotide sequences with specific catalytic activity, have been reported frequently applied in detection assays for such as ions and amino acids, due to the advantage in stability, high cost-effectiveness and modification convenience, by comparison with protein enzymes. The D

• So what makes a FFAR agonist different and

  2022-03-17

  

  So what makes a FFAR1 agonist different and interesting? As shown in the , the cellular mechanism is different from those of present insulin-releasing pharmacotherapies—namely the secretion initiators (sulphonylureas and meglitinides) and the incretin-based secretion potentiators (glucagon-like pept

• By measuring the accumulation of unprenylated Rap a

  2022-03-17

  

  By measuring the accumulation of unprenylated Rap1a as a surrogate marker for the inhibition of FPPS [8], [9], [10], [11], we found that upregulation of FPPS expression in Hela cells reduced the accumulation of unprenylated Rap1a in response to 24h' treatment with 0–50μM ZOL. As expected, cells cult

• To understand the structural basis for

  2022-03-17

  

  To understand the structural basis for the mode of action of indole-based compounds the crystal structures of bound to both the wild type and A128T IN CCDs have been solved. The X-ray crystallography studies have revealed that binds at the IN dimer interface in the principal LEDGF/p75 binding pocket

• The IN gene of the HIV isolate

  2022-03-17

  

  The IN gene of the HIV isolate from Papua (CRF01_AE isolate) contains genetic polymorphisms (Fig. 1A) that encode for variant amino acids in the IN protein, based on the Stanford HIVdb mutation interpretation database (Fig. 1B). These variations slightly changed the three-dimensional structure of IN

• 740 Y-P TLRs were originally identified as pathogen

  2022-03-17

  

  TLRs were originally identified as pathogen-associated molecular pattern recognition receptors that recognized exogenous ligands in response to infection [31]. In cirrhotic mice or patients, the gastrointestinal tract produces and absorbs considerable bacterial LPS with increased permeability of the

16386 records 493/1093 page Previous Next First page 上5页 491492493494495 下5页 Last page